Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 12, 2026

Salesforce Expands AI Skills And Security Push As Stock Pullback Continues

View original at finance.yahoo.com
Salesforce Expands AI Skills And Security Push As Stock Pullback Continues Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI-driven automation and workflow tools can raise switching costs and support longer-term revenue and margin outcomes for Salesforce.

    60% confidence

  • Kanopy's tooling addresses a practical concern for customers as more non-engineers build AI agents inside Salesforce and security teams look for guardrails.

    60% confidence

  • The Pearson partnership can help Salesforce align hiring and training with the AI features it is selling, such as Agentforce and Data 360.

    60% confidence

  • Salesforce is treating AI as an operational shift rather than only a feature addition, evidenced by workforce-wide AI training and new security tooling.

    60% confidence

  • Investors should watch how quickly AI skills and controls are adopted inside customer environments and across Salesforce's own teams.

    60% confidence

  • Heightened attention to AI security through Kanopy and internal training can be seen as a response to regulatory and data privacy risks flagged as potential headwinds if not managed well.

    60% confidence

Data points we hold from this source

Salesforce · stock return-30.0 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Salesforce Expands AI Skills And Security Push As Stock Pullback Continues — Source | Via News | ViaNews EU